The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.
The user is experiencing progressive hair thinning despite using finasteride and dutasteride. A biopsy confirmed male pattern baldness, and minoxidil was suggested as an additional treatment.
The user is experiencing intense hair shedding all over the scalp after applying pyrilutamide to the hairline and taking oral castor oil. They are also using topical finasteride and latanoprost, but are unsure which treatment is causing the shedding.
The conversation discusses concerns about potential side effects, specifically gynecomastia, from taking 1mg of finasteride every other day for hair loss. Bloodwork results were shared, but more information was requested to provide advice.
User experienced side effects from topical finasteride, including penile pain and reduced sexual satisfaction, and is unsure whether to resume or avoid the treatment. They are seeking advice on whether tapering off the drug might help.
A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.
Creatine may increase DHT levels, potentially causing symptoms like acne, oily hair, and hair shedding. Users report mixed experiences, with some avoiding creatine due to hair loss concerns and others seeing no impact.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also inquires about the timeline for the GT20029 phase 3 trial by Kintor.
The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.
Spironolactone and finasteride are not recommended for women planning pregnancy due to birth defect risks. Both need to be stopped months before conception, and finasteride is generally not advised for women.
The conversation is about the long-term safety trial results for pyrilutamide, which are expected soon. Treatments mentioned include Minoxidil, finasteride, and RU58841.
Finasteride may affect prostate sensation and size, with some users reporting easier urination. Concerns exist about prostate shrinkage even at lower doses.
The user has been using topical 0.3% finasteride, 5% minoxidil, and Nizoral for 5 months and is questioning if they are experiencing hair regrowth. The conversation revolves around identifying potential hair regrowth.
A woman is frustrated with her hair loss and the slow, ineffective healthcare system in Canada. She has tried treatments like minoxidil, doxycycline, and kenalog injections, but continues to experience painful inflammation and hair loss.
The conversation discusses whether Pyrilutamide from Koshine is different from Anageninc and if it's effective for hair loss. It also questions if sticking to RU58841 would be better.
A user shared their experience with microneedling and minoxidil for hair loss, avoiding finasteride due to concerns about systemic hormone effects. They reported slight hair regrowth after one month and plan to continue the regimen, noting improvements in skin sensitivity and managing dandruff with anti-dandruff shampoo.
The user is experiencing hair shedding while using finasteride and topical minoxidil with tretinoin, keto shampoo, and dermarolling. They hope the shedding indicates future hair regrowth.
Topical finasteride results in plasma levels 100 times lower than oral finasteride, potentially reducing systemic side effects. Users report similar efficacy with fewer side effects, suggesting a preference for topical application.
Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.
User asks about using eucapil/fluridil with Minoxidil and how to space out application to avoid ineffectiveness. Also inquires about microneedling timing.
The conversation discusses interest in peptides for hair loss, specifically mentioning ahkCU and ghkCU. A user is considering adding ghkCU to their treatment regimen.
A user experiencing diffuse thinning at the hairline after 12 months on finasteride is considering adding minoxidil, dutasteride, or RU58841 to their treatment. Another user suggests adding minoxidil now, holding off on dutasteride, and shares personal side effects from RU58841.
A user is discussing their experience with finasteride for diffuse thinning without a receding hairline, noting a massive shedding phase in the fourth month that is now slowing down. Other replies are off-topic and not relevant to the treatment discussion.
The conversation discusses using minoxidil and finasteride for hair loss, with concerns about absorption and considering adding tretinoin for better results. Microneedling is suggested as a method to improve absorption, with varying depths and frequencies recommended.
The user experienced hair loss after chikungunya and started PRF (platelet-rich fibrin) injections with injectable Dutasteride, noticing new hair growth. They are hopeful for continued improvement.
User tried microneedling with min and fin for hair loss, experienced inflamed scalp and dandruff. Recommends proper disinfection of microneedler to avoid issues.
The user experiences scalp inflammation, especially when oily, despite using treatments like dutasteride, oral minoxidil, RU58841, and nizoral. They recently started cetirizine and are considering benzoyl peroxide wash for relief.